Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 15.12.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6558):

(note that this is only a small subset of citations)

  1. Nagao A, Yeung CH, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thrombosis Research 2019;173:79
    CrossRef
  2. Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics 2019;
    CrossRef
  3. Morfini M, Farrugia A. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. Expert Review of Hematology 2019;12(10):883
    CrossRef
  4. Chelle P, Yeung CHT, Bonanad S, Morales Muñoz JC, Ozelo MC, Megías Vericat JE, Iorio A, Spears J, Mir R, Edginton A. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics 2019;46(5):427
    CrossRef
  5. Delavenne X, Dargaud Y, Ollier E, Négrier C. Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology 2019;85(4):771
    CrossRef
  6. Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology 2019;10:204062071985847
    CrossRef
  7. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda J. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research 2019;174:151
    CrossRef
  8. Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology 2019;12(sup1):1
    CrossRef
  9. Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII. CPT: Pharmacometrics & Systems Pharmacology 2019;
    CrossRef
  10. Yu JK, Iorio A, Edginton AN. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis 2019;3(3):528
    CrossRef
  11. Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS. Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? . Journal of Thrombosis and Haemostasis 2019;17(7):1085
    CrossRef
  12. Pasca S, Zanon E. Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A. Thrombosis Research 2019;183:1
    CrossRef
  13. Stoffman J, Andersson NG, Branchford B, Batt K, D’Oiron R, Escuriola Ettingshausen C, Hart D, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R. Common themes and challenges in hemophilia care: a multinational perspective. Hematology 2019;24(1):39
    CrossRef
  14. Calatayud J, Pérez-Alenda S, Carrasco JJ, Escriche A, Cruz-Montecinos C, Andersen LL, Bonanad S, Querol F, Casaña J. Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia. Physical Therapy 2019;99(4):411
    CrossRef
  15. Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco‐Johnson MJ, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco‐Johnson ML, Funk S, Valentino LA, Hoots WK, DiMichele D, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia 2019;25(5):867
    CrossRef
  16. Gupta S, Shapiro AD. Optimizing bleed prevention throughout the lifespan: Womb to Tomb. Haemophilia 2018;24:76
    CrossRef
  17. Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2018;2(3):535
    CrossRef
  18. Dargaud Y, Delavenne X, Hart D, Meunier S, Mismetti P. Individualized PK-based prophylaxis in severe haemophilia. Haemophilia 2018;24:3
    CrossRef
  19. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis 2018;2(3):607
    CrossRef
  20. Kremer Hovinga ICL, Schutgens REG, van der Valk PR, van Vulpen LFD, Mauser-Bunschoten EP, Fischer K. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia 2018;24(4):e280
    CrossRef
  21. McEneny-King A, Chelle P, Iorio A, Edginton A. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research 2018;170:53
    CrossRef
  22. Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2018;16(7):1437
    CrossRef
  23. Croteau SE. Evolving Complexity in Hemophilia Management. Pediatric Clinics of North America 2018;65(3):407
    CrossRef
  24. Castaman G, Linari S. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. Expert Opinion on Drug Metabolism & Toxicology 2018;14(2):143
    CrossRef
  25. Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology 2017;2017(1):595
    CrossRef
  26. Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thrombosis Research 2017;157:58
    CrossRef
  27. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2017;15(12):2461
    CrossRef
  28. Morfini M. The History of Clotting Factor Concentrates Pharmacokinetics. Journal of Clinical Medicine 2017;6(3):35
    CrossRef
  29. Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. Journal of Thrombosis and Haemostasis 2017;15(6):1103
    CrossRef
  30. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis 2017;117(06):1023
    CrossRef
  31. Gringeri A, Steinitz-Trost K, Doralt J. Current and future approaches to overcoming the challenges of hemophilia treatment personalization. Expert Opinion on Orphan Drugs 2017;5(7):589
    CrossRef
  32. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton A. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics 2017;9(4):47
    CrossRef